RBC Capital Markets

Selected news for the capital firm - RBC Capital Markets, collected since 10/2017. This capital firm shares healthcare news with Wells Fargo Securities, LLC, COVID-19, Wolfe Research, ACO, Biotech and over a hundred others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/12/2022 For Biogen's Aduhelm, narrow coverage from CMS 'could effectively spell the end': analyst FiercePharma ... for Medicare & Medicaid Services becomes final guidance. The proposed restriction—and the complexity involved—has industry watchers worried about the therapy’s future.The CMS proposal “could effectively spell the end for Aduhelm,” RBC Capital Markets analyst Brian Abrahams wrote in a Tuesday note to clients. That’s because older people covered by Medicare make up the bulk of the Alzheimer’s patient population, and restrictive access there would ...
1/11/2022 RBC's Top 30 Global Stock Investments for 2022 | Nasdaq Nasdaq I t will be tough to top the S&P 500's whopper of a performance in 2021. But investors can still look forward to "solid" if more "moderate" returns in the year ahead, says RBC Capital Markets – and perhaps even better with the right stock investments."The overall outlook for the next six to 12 months remains optimistic due to strong assessments for fundamentals, valuations, cash deployment and ...
1/11/2022 Biotech Stocks: The Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer leakherald.com ... higher.Biotech Stocks: Preannouncements MixedExelixis (EXEL) stock toppled 2.5% to 18.27 after the company pre-reported about $300 million in sales of its cancer treatment, Cabometyx. That narrowly beat forecasts for $298 million, RBC Capital Markets analyst Kennen MacKay said in a report to clients.Full-year guidance for $1.325 billion to $1.425 billion in Cabometyx sales “straddles Street estimates for $1.4 billion and adds confidence to Cabo’s ...
1/11/2022 Biotech Stocks: The Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer reportdoor.com ... higher.Biotech Stocks: Preannouncements MixedExelixis (EXEL) stock toppled 2.5% to 18.27 after the company pre-reported about $300 million in sales of its cancer treatment, Cabometyx. That narrowly beat forecasts for $298 million, RBC Capital Markets analyst Kennen MacKay said in a report to clients.Full-year guidance for $1.325 billion to $1.425 billion in Cabometyx sales “straddles Street estimates for $1.4 billion and adds confidence to Cabo’s ...
1/11/2022 wapakdailynews.com Our call of the day from Lori Calvasina at RBC Capital Markets has a few ideas on where investors need to look for stocks to invest in as rates begin to rise. Related Stocks: AMC Entertainment Holdings Inc Alibaba Group Holding Ltd Apple Danaher Corp Delphi Automotive Plc GameStop Corp Moderna Inc NVIDIA Corp Novavax Inc Pfizer Tesla, Inc. Tilray Inc ...
1/10/2022 JPM 2022: Sarepta projects Duchenne muscular gene therapy will go to FDA next year, sees shares crash 15% FierceBiotech Sarepta Therapeutics could ask the FDA as soon as next year to approve its gene transfer therapy for Duchenne muscular dystrophy, the biotech said Monday at the annual J.P. Morgan Healthcare Conference.The therapy, dubbed SRP-9001, showed “highly" statistically significant improvements at 48 weeks in a functional motor ability test.Nonetheless, the company's shares, after being halted in the morning, dropped about 15.5% to $72.20 apiece as of 2:01 ...
1/5/2022 RBC Chooses Amazon, M&T, UnitedHealth as Top 2022 Stocks - TheStreet TheStreet RBC Capital Markets Tuesday named its top 30 stock picks for 2022, including Amazon ( AMZN ) - Get Amazon.com, Inc. Report , Dupont ( DD ) - Get DuPont de Nemours, Inc. Report , M&T Bank ( MTB ) - Get M&T Bank Corporation Report , Mastercard ( MA ) - Get Mastercard Incorporated Class A Report and UnitedHealth ( UNH ) - Get UnitedHealth Group Incorporated Report . “Our U.S. equity strategy team expects 2022 to be a year of solid but more moderate returns ...
1/5/2022 RBC Chooses Amazon, M&T, UnitedHealth As Top 2022 Stocks TheStreet RBC Capital Markets Tuesday named its top 30 stock picks for 2022, including Amazon ( AMZN ) - Get Amazon.com, Inc. Report , Dupont ( DD ) - Get DuPont de Nemours, Inc. Report , M&T Bank ( MTB ) - Get M&T Bank Corporation Report , Mastercard ( MA ) - Get Mastercard Incorporated Class A Report and UnitedHealth ( UNH ) - Get UnitedHealth Group Incorporated Report . “Our U.S. equity strategy team expects 2022 to be a year of solid but more moderate returns ...
1/4/2022 Oil prices steady ahead of OPEC+ output policy meeting brecorder.com MELBOURNE: Oil prices were flat on Tuesday ahead of a meeting where major producers are expected to stick to plans to add supply in February, as soaring COVID-19 cases have yet to spark lockdowns in the biggest fuel-consuming countries.Brent crude futures gained 1 cent to $78.99 a barrel at 0239 GMT, while US West Texas Intermediate (WTI) crude futures slipped 2 cents to $76.06 a barrel.The ...
12/22/2021 HCA names new VP of investor relations Becker's Hospital Review ... in March after a nearly 40-year career with the health system, a Dec. 22 news release shared with Becker's said.Mr. Morgan currently serves as the managing director of healthcare services research for RBC Capital Markets , a Toronto-based investment company he joined in 2008. He previously held senior analyst positions with New York City-based Jefferies and Company and J.C. Bradford in Nashville.Since joining HCA in 1982 ...
12/22/2021 2022 forecast: Biopharma M&A lags in 2021. Will drugmakers still look for bolt-on deals or large transactions? | FiercePharma FiercePharma ... billion biotech takeovers, the accounting firm also sees opportunities for large buyouts of around $50 billion or even a “transact-to-transform” megadeal at $100 billion or more.In a report in December, RBC Capital Markets analysts also projected that “a rebound in M&A is imminent,” given that large companies now have stronger balance sheets while still have looming patent cliffs to fight. Valuations of small- and ...
12/17/2021 Omicron and Delta Could Coexist. What That Would Look Like. - MarketWatch MarketWatch ... by more than 30% over the last two weeks. Hospitalizations and deaths have been rising as well.In most areas where Omicron has spread, it rapidly has displaced Delta as the prevalent strain, wrote RBC Capital Markets analyst Brian Abrahams in a note on Friday.“It may be too early to say whether Delta will become completely outcompeted away, given the different immune profiles of the two viruses — it ...
12/16/2021 Gilead's Yescarta in line for $1.5B sales in earlier lymphoma thanks to game-changing data, fast production turnaround: analyst | FiercePharma FiercePharma ... care in certain patients with aggressive B-cell lymphoma after one prior therapy. For Gilead Sciences’ Yescarta, that indication could mean $1.5 billion in sales over time.That’s the projection analysts at RBC Capital Markets made in a Thursday note to clients after speaking with a lymphoma expert.Yescarta likely won’t get there overnight, as the RBC team sees potential future adoption in second-line large B ...
12/15/2021 HEXO Corp. (HEXO) Q1 2022 Earnings Call alphastreet.com ... Chief Financial OfficerValerie Malone — Chief Commercial OfficerAaron Grey — Alliance Global Partners — AnalystRupesh Parikh — Oppenheimer — AnalystTamy Chen — BMO Capital Markets — AnalystDouglas Miehm — RBC Capital Markets — AnalystJohn Zamparo — CIBC — AnalystAdam Buckham — Scotiabank — Analyst———-To read the full earnings call transcript, click hereAfter record activity, the IPO market has ...
12/15/2021 Why Wall Street Isn't Freaking Out Over Omicron - MarketWatch MarketWatch ... wearing masks at the office and shopping mall, while carrying on with the business of economic recovery.In the weeks since Omicron’s Thanksgiving appearance , U.S. equity strategist Lori Calvasina and her colleagues at RBC Capital Markets have had many meetings with investors to discuss RBC forecasts for 2022. Omicron hasn’t been a major topic.“It hasn’t been the focus of conversation,” Calvasina tells Barron’s. “The ...
12/15/2021 Why Wall Street Isn't Freaking Out Over Omicron | Barron's barrons.com ... wearing masks at the office and shopping mall, while carrying on with the business of economic recovery.In the weeks since Omicron’s Thanksgiving appearance, U.S. equity strategist Lori Calvasina and her colleagues at RBC Capital Markets have had many meetings with investors ...
12/15/2021 BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States | Business Wire Business Wire ... BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU) today announced that it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies, Evercore ISI and RBC Capital Markets as joint book-running managers, and including LifeSci Capital as lead manager and H.C. Wainwright & Co. and Bloom Burton as co-managers (collectively, the “Underwriters”), relating to the public offering of 25,000,000 ...
12/15/2021 BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States Yahoo News ... the "Offering"), BELLUS Health Inc. ("BELLUS Health" or the "Company") (TSX and Nasdaq: BLU) today announced that it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies, Evercore ISI and RBC Capital Markets as joint book-running managers, and including LifeSci Capital as lead manager and H.C. Wainwright & Co. and Bloom Burton as co-managers (collectively, the "Underwriters"), relating to the public offering of 25,000,000 common ...
12/15/2021 BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States | Business & Finance | citizentribune.com citizentribune.com ... BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU) today announced that it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies, Evercore ISI and RBC Capital Markets as joint book-running managers, and including LifeSci Capital as lead manager and H.C. Wainwright & Co. and Bloom Burton as co-managers (collectively, the “Underwriters”), relating to the public offering of 25,000,000 ...
12/15/2021 BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States Business Wire ... BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU) today announced that it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies, Evercore ISI and RBC Capital Markets as joint book-running managers, and including LifeSci Capital as lead manager and H.C. Wainwright & Co. and Bloom Burton as co-managers (collectively, the “Underwriters”), relating to the public offering of 25,000,000 ...